Latest news with #monoclonalAntibodies
Yahoo
02-07-2025
- Business
- Yahoo
Jim Cramer on TG Therapeutics: 'You Should Buy the Stock'
TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 14 stocks Jim Cramer recently looked at. When a caller inquired about the company during the lightning round, Cramer stated: 'I remember when Mike Weiss was an analyst. I always loved the man. I love him now. I think you should buy the stock.' A scientific researcher holding a petri dish containing a glycoengineered monoclonal antibody. TG Therapeutics, Inc. (NASDAQ:TGTX) develops and commercializes therapies for B-cell mediated diseases, and it offers BRIUMVI for multiple sclerosis and is advancing a pipeline of monoclonal antibodies and kinase inhibitors targeting autoimmune conditions and blood cancers. ClearBridge Investments stated the following regarding TG Therapeutics, Inc. (NASDAQ:TGTX) in its Q4 2024 investor letter: '2024 proved a particularly active year for new idea generation: we added 23 new investments while exiting 29 due to a variety of considerations, including acquisitions, market capitalization constraints, and our assessment of forward return potential. While many of the new investments we made during the year are of relatively modest size, we will continue to build these positions over time provided company execution and end market prospects remain intact. In the fourth quarter we initiated five new investments: Oscar Health,TG Therapeutics, Inc. (NASDAQ:TGTX), Clearwater Analytics, Fluor and Modine. While we acknowledge the potential of TGTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
24-06-2025
- Health
- Yahoo
Vasculitis Market Analysis Report 2025-2035, Competitive Analysis of GlaxoSmithKline, Mitsubishi Tanabe Pharma, Novartis, and Amgen
Vasculitis, a severe blood vessel condition, drives the global market's growth due to advancements in biologic treatments like monoclonal antibodies. Enhanced diagnostics and personalized medicine bolster this trend. North America leads the market, backed by advanced healthcare infrastructure and research funding. Rising cases, driven by aging populations and lifestyle factors, highlight demand, while high treatment costs and unmet needs in rare forms pose challenges. For companies, focusing on innovation in biologics and strategic partnerships is key to competitive advantage. Discover insights on vasculitis market trends and opportunities for growth. Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Vasculitis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to is a rare but severe condition that results in inflammation of blood vessels, leading to a wide range of symptoms that can disrupt normal blood flow and damage affected organs. The variability in its presentation, from mild cases to severe manifestations, necessitates the development of targeted therapies. The growing focus on biologic treatments, such as monoclonal antibodies and advanced immunomodulators, will continue to play a key role in driving the global vasculitis market forward during the forecast advancements in diagnostics, as well as a growing understanding of the pathophysiology of vasculitis, are also expected to contribute significantly to market expansion. Personalized medicine and the integration of digital health solutions in treatment management are poised to revolutionize the therapeutic landscape for vasculitis America is projected to remain the dominant region in the global vasculitis market. This is primarily due to the region's advanced healthcare infrastructure, higher levels of patient awareness, and robust government funding aimed at fostering research into autoimmune diseases like vasculitis. How Can This Report Add Value to an Organization?Product/Innovation Strategy: The global vasculitis market is witnessing a surge in product innovations, particularly in the field of biologics and personalized medicine. This report provides valuable insights into the development of new treatment strategies, helping companies identify new product opportunities, particularly in biologic therapy and patient management Strategy: Companies aiming to secure or enhance their market share in the global vasculitis market should focus on improving the efficacy and safety profiles of existing therapies, and exploring new biologic treatment combinations to offer personalized care solutions. Companies can also strengthen their position through strategic partnerships, collaborations with research institutions, and investments in early-stage - Drivers and LimitationsThe global vasculitis market is witnessing rising demand due to several key drivers: The rise in vasculitis cases is driven by an aging population, lifestyle factors, and improved awareness and diagnosis Biologics and immunomodulators are revolutionizing vasculitis treatment with more targeted and effective therapies Enhanced imaging, biomarkers, and genetic tests are enabling earlier and more accurate vasculitis diagnosis. Limitations: High costs of biologic therapies restrict access for some patients, particularly in low-income regions There is an unmet need for effective treatments for specific rare and refractory forms of vasculitis Companies Featured GlaxoSmithKline Mitsubishi Tanabe Pharma Corporation Novartis AG Amgen Key Topics Covered: Executive SummaryMarket/Product DefinitionInclusion and Exclusion1. Global Vasculitis Market: Industry Outlook1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis of Vasculitis1.2.1 By Region1.3 Market Trends1.4 Clinical Trials Analysis1.4.1 By Phase1.5 Regulatory Landscape Analysis1.5.1 Legal Requirement and Framework in U.S.1.5.2 Legal Requirement and Framework in E.U.1.5.3 Legal Requirement and Framework in Asia-Pacific1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Restraints1.6.4 Market Opportunities2. Global Vasculitis Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Vasculitis Market (by Country)2.1.3.1.1 U.S.2.1.3.1.2 Canada2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Vasculitis Market (by Country)2.2.3.1.1 Germany2.2.3.1.2 France2.2.3.1.3 Italy2.2.3.1.4 U.K.2.3 Asia-Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia-Pacific Vasculitis Market (by Country)2.3.3.1.1 Japan3. Global Vasculitis Market: Competitive Benchmarking and Company Profiles3.1 Competitive Landscape3.1.1 Key Strategies and Developments3.1.1.1 Funding Activities3.1.1.2 Mergers and Acquisitions3.1.1.3 Regulatory Approvals3.1.1.4 Partnerships, Collaborations and Business Expansions3.1.2 Key Developments Analysis3.2 Company Profiles3.2.1 Company Overview3.2.2 Product Portfolio3.2.3 Target Customers/End Users3.2.4 Key Personnel3.2.5 Analyst View4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medical News Today
10-06-2025
- Health
- Medical News Today
How Tremfya works: Mechanism of action explained
How it works How long it takes to work Tremfya (guselkumab) is a prescription drug that treats psoriatic arthritis, plaque psoriasis, and ulcerative colitis. Its mechanism of action is binding to interleukin-23 that's overactive. Tremfya belongs to a class of medications called interleukin-23 blockers. It's a type of biologic called a monoclonal antibody, which is a protein that attaches to substances in the body. Tremfya works by binding to interleukin-23 (a protein in the body) that's overactive. By binding to this protein, Tremfya decreases how active your immune system is to ease inflammation and decrease symptoms of your condition. The way a drug works is known medically as its mechanism of action. The mechanism of action for Tremfya may vary depending on the condition it's being used to treat. Tremfya is approved by the Food and Drug Administration (FDA) to treat certain conditions, including psoriatic arthritis. When you have psoriatic arthritis, your immune system (your body's defense against infections) is overactive. It attacks healthy tissues and cells, causing joint pain and inflammation. It also causes your body to make too many skin cells, leading to a buildup of cells and areas called plaques. These plaques are flushed, itchy patches on your skin. Tremfya is FDA-approved to treat moderate to severe plaque psoriasis. This condition is one of many types of psoriasis. When you have plaque psoriasis, your immune system is overactive. It causes your body to make too many skin cells, leading to a buildup of cells and areas called plaques. These plaques are itchy patches on your skin. They may look pink or be darker than your skin color. Sometimes, they may look white and scaly. Tremfya may be an option for plaque psoriasis treatment if you can receive either: systemic therapy (treatment that affects your whole body), or phototherapy (treatment with light) Tremfya is FDA approved to treat moderate to severely active ulcerative colitis (UC) in adults. When UC is active, it's causing symptoms. Tremfya is prescribed to help put UC in remission and keep it there. With remission, you have few or no symptoms of the condition. Ulcerative colitis is a type of inflammatory bowel disease (IBD) that affects the colon and rectum. It's thought to result from overactivity in a person's immune system. With UC, you have inflammation in your colon, rectum, or both. In severe cases, ulcers can also form in these areas. Symptoms of this condition include blood in your stool, diarrhea, abdominal pain or cramps, and weight loss. For this condition, Tremfya is typically prescribed alone. Your doctor may also prescribe nonbiologics to treat an ulcerative colitis flare-up. Tremfya is FDA approved to treat Crohn's disease. Like UC, Crohn's disease is a type of IBD. Unlike UC, which affects the colon and rectum, Crohn's disease can affect your entire digestive system, including your stomach, intestines, and colon. To find out more about Crohn's disease, visit our IBD hub. In clinical trials, people with plaque psoriasis often experienced a reduction in symptoms after receiving three doses of Tremfya over 16 weeks. Also, more than half of the people receiving Tremfya for psoriatic arthritis in clinical trials experienced a decrease in symptoms after 16 weeks of treatment. In a clinical trial of Tremfya for UC, more than half of the people receiving the drug experienced a decrease in symptoms after 12 weeks. Some people also experienced remission (few or no symptoms of UC). If you have more questions about how long it takes for Tremfya to work, talk with your doctor or pharmacist. Disclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses. Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources to ensure content accuracy and integrity. You can learn more about how we ensure our content is accurate and current by reading our editorial policy.
